TMO
Thermo Fisher ScientificBNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-17
Current thesis
Bull case assumes sustained instrument and consumables demand, continued margin expansion from operating leverage, and successful bolt‑on M&A driving multiple expansion toward the top of the analyst range.
Posture
Constructive
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-07-23 · BMO.
What can break
Cyclical weakness in instrument orders and consumables demand
Momentum
41
Value
62
Sentiment
65
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $638.08 · Bull $787.50 · Bear $510.00
Earnings
2026-07-23 · BMO
Data freshness
Prices
As of 2026-07-17
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-17 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-30 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-17
Investment thesis
As of 2026-07-17
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $595.54
Why
Momentum41 · Δ7d -22.3
Value62 · Δ7d -0.2
Sentiment65 · Δ7d -9.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
41
26% active weight
Current posture
7d trendImproving
Δ7d
-22.3
Δ21d
-5.4
Value
62
39% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.2
Sentiment
65
34% active weight
Current posture
7d trendSoftening
Δ7d
-9.7
Δ21d
-8.6
Why this grade
Composite grade B. Momentum 41.4 / Value 62.0 / Sentiment 65.2
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$197.88B
Beta
0.93
Shares Out
371.62M
P/E (TTM)
35.3
P/S (TTM)
5.25
P/FCF (TTM)
41.85
Rev YoY
+6.2%
EPS YoY
+11.3%
Gross Margin
+40.1%
Op Margin
+17.2%
Net Debt
$30.75B
Current Ratio
1.53
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology